Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma

BackgroundThere is no neoadjuvant immunotherapy for early-stage oral cancer patients. We report a single-arm, open-label, pilot clinical trial assessing the efficacy and safety of topical toll-like receptor-7 (TLR-7) agonist, imiquimod, utilized in a neoadjuvant setting in early-stage oral squamous...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Angela J. Yoon, Richard D. Carvajal, Evan M. Graboyes, John M. Kaczmar, William G. Albergotti, Alexandra E. Kejner, Scott H. Troob, Elizabeth Philipone, Jean-Sebastien Anoma, Kent E. Armeson, Elizabeth G. Hill, Mary S. Richardson, Tina R. Woods, Bhishamjit S. Chera, Farzad Nourollah-Zadeh, Byung J. Lee, Subramanya Pandruvada, Antonis Kourtidis, Christina Kingsley, Elizabeth C. O’Quinn, Stephanie Mills, Victoria C. Jordan, Mike Spencer, Danielle Fails, Trevor D. McKee, Mark Zaidi, Alan Brisendine, Shane Horn, Shikhar Mehrotra, Besim Ogretmen, Jason G. Newman
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2025-01-01
coleção:	Frontiers in Immunology
Assuntos:	oral cancer neoadjuvant clinical trial toll-like 7 receptor agonist imiquimod immunotherapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1530262/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!